Reapplix Private Circle For Diabetic Foot Ulcers
October 7, 2024
Reapplix Private Circle For Diabetic Foot Ulcers
Reapplix, an international wound care company, has recently launched a RegenMed Private Circle aggregating clinical and long-term outcomes data on its personalized diabetic foot ulcer product. The diabetic foot ulcer market value is estimated at $5.2 billion.
About 60% of all patients experience a wound that does not heal. If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound. For about 20% of patients, treatment ends in amputation within one year.
The Reapplix Circle will help the company, its clinical customers, and their patients further support the safety and efficacy of its products.
For more information on this Circle, including applying to join, see here.
Reapplix Private Circle For Diabetic Foot Ulcers
October 7, 2024
Reapplix, an international wound care company, has recently launched a RegenMed Private Circle aggregating clinical and long-term outcomes data on its personalized diabetic foot ulcer product. The diabetic foot ulcer market value is estimated at $5.2 billion.
About 60% of all patients experience a wound that does not heal. If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound. For about 20% of patients, treatment ends in amputation within one year.
The Reapplix Circle will help the company, its clinical customers, and their patients further support the safety and efficacy of its products.
For more information on this Circle, including applying to join, see here.
